FGC
ANIK icon

Financial Gravity Companies’s Anika Therapeutics ANIK Stock Holding History

Financial Gravity Companies’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$52K Buy
+1,365
New +$49.3K 0.05% 316
2018
Q1 		$3K Sell
70
-2,933
-98% -$166K ﹤0.01% 824
2017
Q4 		$200K Buy
+3,003
New +$166K 0.23% 83

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Financial Gravity Companies's ANIK Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Anika Therapeutics (ANIK) in Q4 2018: 1,365 shares worth $52K. The stake represents 0.05% of the portfolio and ranks #316 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in ANIK as recently as Q1 2018.

Financial Gravity Companies first reported a position in ANIK in Q4 2017 and has held it in 3 quarters since. The position peaked at $200K in Q4 2017. 162 funds tracked by Wall St. Rank hold ANIK as of Q4 2018.

  • Financial Gravity Companies held 1,365 shares of Anika Therapeutics worth $52K as of Q4 2018.
  • Anika Therapeutics was a new Financial Gravity Companies position in Q4 2018.
  • Anika Therapeutics made up 0.05% of Financial Gravity Companies's portfolio in Q4 2018, its #316 holding.
  • Financial Gravity Companies first reported a position in Anika Therapeutics in Q4 2017 and has held it in 3 quarters since.
  • Financial Gravity Companies's Anika Therapeutics position peaked at $200K in Q4 2017.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.